JUNIPER, a randomized, phase III trial of patients with stage IV non–small cell lung cancer and a detectable Kristen rat sarcoma (KRAS) mutation in codons 12 or 13 whose condition progressed after platinum-based chemotherapy and up to 1 additional therapy (could include immune checkpoint inhibitors), reported prolonged progression-free survival (PFS) but not overall survival (OS) among patients who were receiving abemaciclib versus those who were receiving erlotinib. The gene discussed is KRAS; the disease is lung cancer.